SCHEMBL1023364

SCHEMBL1023364

C=CCOC(=O)CC(N)C(=O)OCC=C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.46
TSHR P16473 2/20 0.42
MAPT P10636 3/20 0.38
CACNA1B Q00975 1/20 0.38
APBA1 Q02410 1/20 0.38
CYP3A4 P08684 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
ALDH1A1 P00352 4/20 0.35
HSD17B10 Q99714 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
PKM P14618 1/20 0.35
GAA P10253 1/20 0.33
GRIK1 P39086 2/20 0.32
GRIK2 Q13002 2/20 0.32
KDM4E B2RXH2 1/20 0.32
TP53 P04637 1/20 0.32
HPGD P15428 1/20 0.32
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30
POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL176160 1.00 TDP1 (0.46) TDP1TSHRMAPTCACNA1BAPBA1
SCHEMBL2201786 0.86 GRIK1 (0.47) TDP1TSHRMAPTCACNA1BAPBA1
SCHEMBL2201794 0.86 GRIK1 (0.47) TDP1TSHRMAPTCACNA1BAPBA1
Hydrochloric Acid SCHEMBL29425835 0.85 GRIK1 (0.46) TDP1TSHRMAPTCACNA1BAPBA1
SCHEMBL6532116 0.84 MAPT (0.38) TDP1TSHRMAPTCACNA1BAPBA1
SCHEMBL2515415 0.84 MAPT (0.42) TDP1TSHRMAPTCACNA1BAPBA1
SCHEMBL1023366 0.84 MAPT (0.38) TDP1TSHRMAPTCACNA1BAPBA1
SCHEMBL10972597 0.84 MAPT (0.42) TDP1TSHRMAPTCACNA1BAPBA1
SCHEMBL22984932 0.83 SMN1; SMN2 (0.40) TDP1TSHRMAPTCACNA1BAPBA1
Hydrochloric Acid SCHEMBL8140432 0.82 MAPT (0.37) TDP1TSHRMAPTCACNA1BAPBA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299128-B2 Compositions comprising polymeric micelles for drug delivery INTEZYNE TECHNOLOGIES, INC. (US) 2012-10-30 US claimed
US-8268936-B2 Synthesis of hybrid block copolymers and uses thereof INTEZYNE TECHNOLOGIES, INC. (US) 2012-09-18 US claimed
US-8263665-B2 Polymeric micelles for drug delivery INTEZYNE TECHNOLOGIES, INC. (US) 2012-09-11 US claimed
US-20120148631-A1 PEGYLATED POLYPLEXES FOR POLYNUCLEOTIDE DELIVERY INTEZYNE TECHNOLOGIES, INCORPORATED (US) 2012-06-14 US claimed
US-20110124840-A1 Synthesis of Homopolymers and Block Copolymers INTEZYNE TECHNOLOGIES, INC. 2011-05-26 US claimed
US-20110091534-A1 COMPOSITIONS COMPRISING POLYMERIC MICELLES FOR DRUG DELIVERY INTEZYNE TECHNOLOGIES, INC. (US) 2011-04-21 US claimed
US-20110021718-A1 SYNTHESIS OF HYBRID BLOCK COPOLYMERS AND USES THEREOF INTEZYNE TECHNOLOGIES (US) 2011-01-27 US claimed
US-20100159020-A1 POLYMERIC MICELLES FOR DRUG DELIVERY INTEZYNE TECHNOLOGIES, INC. (US) 2010-06-24 US claimed
US-7638558-B2 drug loaded micelle of a triblock polymer tert-butylphenylsilylpropene-polyethylene glycol-b-poly(tert-butylaspartic acid-b-polyphenylalanine-copoly( tert-buyltyrosine) has a drug-loaded inner core, a crosslinked outer core, and a hydrophilic shell INTEZYNE TECHNOLOGIES, INC. (US) 2009-12-29 US claimed
US-7601796-B2 polyamideether copolymer has a hydrophilic polyethylene glycol and a hydrophobic polyamino acid blocks; modified polyethylene glycol homopolymer; forming conjugate polymer drug; resin peptides; use in pharmaceutically acceptable compositions INTEZYNE TECHNOLOGIES, INC. (US) 2009-10-13 US claimed
EP-1848460-A2 SYNTHESIS OF HOMOPOLYMERS AND BLOCK COPOLYMERS Intezyne Technologies Incorporated (US) 2007-10-31 EP claimed
US-20070059843-A1 Method of high-speed detection for biological analyte JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2007-03-15 US claimed
WO-2006086325-A2 SYNTHESIS OF HOMOPOLYMERS AND BLOCK COPOLYMERS INTEZYNE TECHNOLOGIES, INCORPORATED (US) 2006-08-17 WO claimed
JP-10087684-A None JP disclosed
US-20230167154-A1 MELANOCORTIN 1 RECEPTOR LIGANDS AND METHODS OF USE H LEE MOFFITT CANCER CT & RES (US) 2023-06-01 US disclosed
US-11230568-B2 Melanocortin 1 receptor ligands and methods of use H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2022-01-25 US disclosed
WO-2000035998-A2 ASSOCIATION OF COMPOUNDS IN CARBON DIOXIDE AND THE GELS AND/OR FOAMS FORMED THEREFROM YALE UNIVERSITY (US) 2000-06-22 WO disclosed
JP-H1087684-A N-GLYCOSIDE TYPE GLYCOLIPID HAVING LONG ALKYL ASPARTATE AS HYDROPHOBIC PART AGENCY OF IND SCIENCE & TECHNOL 1998-04-07 JP disclosed
US-5653970-A CLEANING COMPOUNDS; COSMETICS LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) 1997-08-05 US disclosed
US-5641480-A ENHANCED STABILITY AND/OR VISCOSITY, CLARITY LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) 1997-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120148631-A1 PEGYLATED POLYPLEXES FOR POLYNUCLEOTIDE DELIVERY PARN, PUF60, PARG TDP1 271/4885TSHR 3477/4885MAPT 2732/4885
US-20110124840-A1 Synthesis of Homopolymers and Block Copolymers PARG, PCNA, PARN TDP1 1461/4885TSHR 4590/4885MAPT 1435/4885
US-11230568-B2 Melanocortin 1 receptor ligands and methods of use MC1R, MC3R, MC5R TDP1 4446/4885TSHR 93/4885MAPT 1995/4885
US-20110091534-A1 COMPOSITIONS COMPRISING POLYMERIC MICELLES FOR DRUG DELIVERY ABCB4, ABCB11, CLTB TDP1 2472/4885TSHR 3728/4885MAPT 104/4885
US-20230167154-A1 MELANOCORTIN 1 RECEPTOR LIGANDS AND METHODS OF USE MC1R, MC3R, MC5R TDP1 4446/4885TSHR 93/4885MAPT 1995/4885
US-20100159020-A1 POLYMERIC MICELLES FOR DRUG DELIVERY ABCB4, CLTB, CD47 TDP1 2638/4885TSHR 3168/4885MAPT 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.